The recombinant protein market deals with proteins that are generated through genetic engineering and dna recombination techniques. These proteins are widely utilized in biotechnology and pharmacological research owing to their close resemblance with human proteins. Recombinant proteins find extensive usage in producing therapeutic drugs for treating cancer, anemia, growth deficiencies and other such medical conditions. They help in developing novel treatment methods as recombinant proteins can be mass produced and refined to target specific molecular functions inside the human body. Further, the expanding biologics industry and rapid advancements in gene therapy have bolstered the demand for recombinant proteins from pharmaceutical and research organizations.
The Global recombinant protein market is estimated to be valued at US$ 3607.34 Bn in 2024 and is expected to exhibit a CAGR of 7.3% over the forecast period 2024 to 2031.
Key Takeaways
Key players operating in the Recombinant Protein Market Growth are Merck KGaA, Allergan plc ( A subsidiary of AbbVie Inc.), Novartis AG, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Bausch & Lomb, Inotek, Jadran-galenski laboratorij d.d. JGL d.d, Aerie Pharmaceutical (A subsidiary of Alcon Management S. A) and Mylan N.V (A subsidiary of Viatris Inc.). These players are investing heavily in product innovation and manufacturing expansions to strengthen market presence.
The recombinant protein market offers promising growth opportunities in disease specific drug discovery, vaccine development and cell therapy. With rising investments in biotechnology, adoption of recombinant proteins is growing across research organizations and biopharma companies engaged in developing novel therapeutics.
Major players are strategizing global expansion plans by setting up manufacturing units, laboratories and research facilities in high growth markets like North America, Europe, China and India. This allows them to capitalize on large patient pools and cater to the local demand. Partnerships with regional players further aid their worldwide distribution and commercialization efforts.
Market drivers:
- Increasing prevalence of chronic diseases like cancer, cardiac ailments and diabetes is propelling the demand for advanced biologic drugs developed using recombinant protein technology.
- Growing aging population prone to health issues has enhanced the utilization of recombinant proteins in therapeutics and medical research.
Market restraints:
- High costs associated with production and purification processes of recombinant proteins pose challenges in wide commercialization and price sensitiveness in developing nations.
- Stringent regulatory approvals and safety protocols increase compliance burdens delaying product launches.
Segment Analysis
The recombinant protein market is dominated by therapeutic proteins sub segment. These proteins are used to treat and cure many chronic and life threatening diseases like cancer, respiratory diseases, cardiovascular diseases, hematological diseases, infectious diseases etc. Therapeutic proteins include recombinant monoclonal antibodies, therapeutic enzymes, recombinant hormones and vaccines. They help in boosting immunity, restore enzyme activity, act as antagonists or help in neutralizing or blocking disease causing agents. Due to their ability to treat serious ailments affecting large population, therapeutic proteins sub segment holds over 60% share of overall recombinant protein market.
Global Analysis
North America holds the largest share in global recombinant protein market. Factors such as increasing prevalence of chronic diseases, high healthcare expenditure, availability of advanced healthcare facilities and presence of major recombinant protein manufacturers in the region driving the market growth. Asia Pacific is the fastest growing market owing to rising healthcare awareness, growing middle class population, improving healthcare infrastructure along with increasing government investments in healthcare sector in emerging economies like China and India. Additionally, rising incidence of chronic diseases due to changing lifestyle and growing geriatric population also supplementing the APAC market growth.
Get more insights on Recombinant Protein Market
Comments
0 comment